Dose-Escalation Study of GSK2126458 (FTIH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00972686 |
Recruitment Status :
Completed
First Posted : September 7, 2009
Last Update Posted : May 9, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumours | Drug: GSK2126458 | Phase 1 |
This study is a Phase I, first-time-in-human dose escalation study in subjects with refractory solid tumors or lymphoma. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.
Subjects with solid tumors or lymphoma will initially receive oral GSK2126458 daily for 28 consecutive days in each 28 day cycle. Subjects may be dosed once or twice a day or may be dosed on an intermittent schedule depending on the safety, pharmacokinetic and pharmacodynamic results that become available as the study progresses. The starting dose will be 0.1 mg once a day. Expansion of some cohorts will be conducted to test tumor pharmacodynamics, further explore the toxicity profile and to look for preliminary evidence of activity in subjects with tumors with PIK3CA mutations. The recommended Phase II dose will be the lowest dose explored (at or below MTD) that maintains biologic activity with an acceptable tolerability profile.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 79 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma |
Actual Study Start Date : | August 31, 2009 |
Actual Primary Completion Date : | December 12, 2012 |
Actual Study Completion Date : | March 31, 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: GSK2126458
GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
|
Drug: GSK2126458
GSK2126458 is an experimental treatment for patients with cancer. |
- Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined [ Time Frame: Subjects continue on study until disease progression or consent withdrawal ]
- Metabolic profile in plasma at the maximum tolerated dose [ Time Frame: Subjects continue on study until disease progression or consent withdrawal ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy, or lymphoma
- Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
- Female or male that is willing to take measures to avoid pregnancy in self or a partner, including abstinence, or double barrier method.
- Adequate organ system function
Exclusion Criteria:
- Use of an investigational anti-cancer medication within 28 days or 5 half-lives preceding the first dose of GSK2126458.
- Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C
- Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks.
- Prior use of any PI3K inhibitor.
- Current use of a prohibited medication or requires any of these medications during treatment with GSK2126458.
- Presence of an active gastrointestinal disease or other condition known to interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
- Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except alopecia.
- QTc interval ≥ 480 msecs.
- History of acute coronary syndromes; Class II, III, or IV heart failure; stroke or subarachnoid hemorrhage.
- Systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg.
- Previously diagnosed Type 1 diabetes mellitus. Subjects with Type 2 diabetes are prohibited in the dose escalation part of the study.
- Symptomatic or untreated leptomeningeal or brain metastases.
- Primary malignancy of the central nervous system.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00972686
United States, California | |
GSK Investigational Site | |
San Francisco, California, United States, 94115 | |
United States, New Jersey | |
GSK Investigational Site | |
New Brunswick, New Jersey, United States, 08901 | |
United States, North Carolina | |
GSK Investigational Site | |
Chapel Hill, North Carolina, United States, 27599-7600 | |
United States, Texas | |
GSK Investigational Site | |
Dallas, Texas, United States, 75246 | |
GSK Investigational Site | |
Houston, Texas, United States, 77030 | |
United States, Utah | |
GSK Investigational Site | |
Salt Lake City, Utah, United States, 84112-5550 | |
United States, Washington | |
GSK Investigational Site | |
Seattle, Washington, United States, 98109 | |
Netherlands | |
GSK Investigational Site | |
Amsterdam, Netherlands, 1066 CX | |
GSK Investigational Site | |
Utrecht, Netherlands, 3584 CX |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Study Data/Documents: Statistical Analysis Plan

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00972686 |
Other Study ID Numbers: |
112826 |
First Posted: | September 7, 2009 Key Record Dates |
Last Update Posted: | May 9, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. |
solid tumors lymphoma Phosphoinositide 3-kinase inhibitor |